Cassava Science: Journal of Neuroscience Review Shows No Evidence of Data Manipulation
Cassava Sciences (SAVA) has been informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article it published in July 2012 describing a new approach to treating Alzheimer’s disease. The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Company’s lead drug candidate for the proposed treatment of Alzheimer’s disease.
From Cassava Sciences
Remi Barbier, President & CEO, Cassava Sciences, said “I’ve never doubted the integrity of our people or science. We remain focused on conducting a Phase 3 clinical program of simufilam in people with Alzheimer’s disease. It’s an important endeavor, notwithstanding pundits who may be louder than they are learned. We’ll stay the course until our job is done.”